Business Context and Reporting Period
The supplied filing is Blade Air Mobility, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022; it does not match the requested company name, Strata Critical Medical, Inc. Blade operates an asset-light air mobility platform using third-party aircraft operators across Short Distance, MediMobility Organ Transport, and Jet and Other services. The company changed its fiscal year-end from September 30 to December 31 effective in 2022.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $45.7 million | $20.3 million | $108.0 million | $42.5 million |
| Gross profit | $9.3 million | $4.5 million | $17.3 million | $8.9 million |
| Gross margin | 20% | 22% | 16% | 21% |
| Loss from operations | $(10.4) million | $(9.7) million | $(33.9) million | $(21.7) million |
| Operating margin | (23%) | (48%) | (31%) | (51%) |
| Net loss | $(9.2) million | $(9.2) million | $(11.8) million | $(37.7) million |
| Net loss per share | $(0.13) | $(0.13) | $(0.17) | $(0.77) |
- Q3 revenue increased 125%; nine-month revenue increased 154% year over year.
- Q3 revenue by line: Short Distance $20.4 million, MediMobility Organ Transport $20.2 million, and Jet and Other $5.1 million.
- Nine-month revenue by line: Short Distance $35.6 million, MediMobility Organ Transport $50.1 million, and Jet and Other $22.3 million.
- Seats flown on passenger flights increased to 28,440 in Q3 and 75,175 for the nine-month period, excluding Blade Europe flights.
- Net cash used in operating activities was $28.0 million for the nine months, compared with $15.6 million in the prior-year period.
- Investing activities provided $78.9 million, principally from $248.4 million of short-term investment sales, partly offset by $48.1 million for the Blade Europe acquisition and $120.5 million of investment purchases.
- At September 30, cash and cash equivalents were $51.8 million, restricted cash was $1.1 million, and short-term investments were $150.4 million.
- The balance sheet showed no conventional debt or note payable, but included $9.1 million of warrant liabilities and $17.1 million of operating lease liabilities.
- Total assets were $326.7 million and stockholders’ equity was $282.7 million.
Material Changes Versus the Prior Comparable Period
- MediMobility Organ Transport revenue increased 801% in Q3 and 877% for the nine months, primarily due to the Trinity acquisition, new hospital clients, and higher trip volume and pricing.
- Short Distance revenue increased 52% in Q3 and 76% for the nine months, supported by U.S. pricing increases, higher demand and utilization, the Canadian launch, airport-transfer growth, and one month of Blade Europe activity.
- Cost of revenue rose faster than revenue, reaching 80% of revenue in Q3 versus 78% and 84% for the nine months versus 79%. Management attributed the pressure to product mix, below-breakeven airport-transfer routes, and Canadian operations.
- General and administrative expense increased 31% in Q3 and 57% for the nine months, reflecting personnel growth, acquisition-related amortization, incentive accruals, and legal, regulatory, and transaction costs.
- Non-operating results improved primarily because the fair value of warrant liabilities declined, producing $22.2 million of non-cash income for the nine months versus an $18.3 million non-cash loss in the prior-year period.
- Blade acquired Blade Europe on September 1, 2022 for $48.1 million in cash. The preliminary purchase accounting included $28.9 million of identifiable intangible assets and $19.0 million of goodwill. Acquisition costs of $2.8 million were expensed.
Outlook, Risks, Contingencies, and Unusual Items
- Management expects continued near-term net losses but stated that cash, cash equivalents, and short-term investments should fund current operational needs for at least 12 months from filing and that no additional capital is expected to be needed for the current business plan over that period.
- Management reported that U.S. Short Distance revenue exceeded pre-pandemic levels in Q3, while Canadian revenue remained below pre-pandemic levels because of weaker business travel in Vancouver.
- Blade remains exposed to COVID-19 travel demand, inflation and fuel costs, aircraft availability, third-party operator performance, aviation regulation, safety events, technology failures and cybersecurity, competition, international expansion, acquisition integration, and the uncertain timing and certification of electric vertical aircraft.
- Remaining contractual aircraft-operator commitments totaled approximately $1.8 million for 2022, $11.4 million for 2023, $15.9 million for 2024, $14.7 million for 2025, and $7.2 million annually for each year from 2026 through 2032. Certain commitments may be terminated for travel restrictions or convenience.
- Trinity received a federal grand jury subpoena for records related to transplant transportation services and is cooperating. The filing does not state a probable loss or financial impact.
- The Shoreline Aviation litigation was dismissed with prejudice in March 2022, with no admission of liability by Blade.
- Disclosure controls were deemed ineffective because of a material weakness in the framework and evidentiary support used to assess internal controls over financial reporting. Blade Europe was excluded from the control evaluation while being integrated. Management planned remediation during 2022.
- Subsequent to quarter-end, Blade granted approximately 4.6 million RSUs in November 2022 and granted additional executive RSUs totaling approximately 4.2 million shares on November 8–9, 2022.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Blade Air Mobility, Inc., not Strata Critical Medical, Inc.
- Assess whether revenue growth, particularly from MediMobility Organ Transport acquisitions, is translating into improved gross margins and a path toward operating profitability.
- Reconcile liquidity against the $28.0 million operating cash burn, aircraft commitments, lease obligations, acquisition strategy, and expected continuing losses.
- Separate recurring operating performance from non-cash warrant-liability gains and realized investment losses.
- Review the Blade Europe purchase-price allocation, integration progress, and the effect of its long-term aircraft operator agreement.
- Monitor the federal grand jury subpoena, regulatory matters, and the material weakness remediation status.
- Evaluate potential dilution from approximately 14.2 million warrants, 7.6 million options, 2.4 million unvested restricted shares, and subsequent RSU grants.